Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $4.30
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.41M
Market Cap
$582.46M
Enterprise Value$376.76M
Total Cash (Recent Filing)$146.44M
Total Debt (Recent Filing)$29.65M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 06, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding172,836,930
10 Day Avg. Volume1,025,953
30 Day Avg. Volume1,408,876
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue1.39K
Enterprise Value/Gross Profit-5.02K
Enterprise Value/Ebitda-3.24
Forecast
1Y Price Target
$8.83Price Target Upside162.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market DevelopmentIncreased U.S. aPAP prevalence may indicate improved awareness and diagnosis rates, benefiting future market development for Molbreevi.
Market ExpansionThe aPAP patient population in the US is now estimated to be 50% greater than originally thought, which supports a higher price target for the company's stock.
Regulatory ProgressSavara's active dialogue with the FDA on comparability requirements is a positive step towards regulatory compliance and market readiness.
Bears Say
Regulatory UncertaintyThere is uncertainty over whether the FDA will call an AdCom for Molbreevi, which could affect both the timeline and the focus of the review.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $4.29 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $582.46M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Nov 06, 2025 which is in 23 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Aug 13, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.13.
How many shares outstanding does Savara have?
Savara has 172,836,930 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.83 (162.02% Upside)
$8.83 (162.02% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 83.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.38%
12-Months-Change
Fundamentals
Return on Equity
-99.30%
Trailing 12-Months
Asset Growth
17.25%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$8.83
▲(162.02% Upside)
Technical Analysis
Ownership Overview
12.67% Insiders
8.05% Mutual Funds
0.02% Other Institutional Investors
70.11% Public Companies and
Individual Investors